Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of V110 (Pneumovax 23) New vs Current Process in Healthy Adults
NCT00127153Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2005
- Primary completion
- May 2005
- Modality
- Split/Subunit Vaccines
01
Overview
A Phase 3 trial of 23-valent pneumococcal polysaccharide vaccine in pneumococcal infection, sponsored by Merck & Co.. Started Mar 2005; status: completed.
02
Drugs
23-valent pneumococcal polysaccharide vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT00127153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00127153.